Cardurion Pharmaceuticals Presents Preclinical Data for CRD-733 at the American Heart Association Scientific Sessions and Announces Initiation of Phase 1b Study in Patients with Heart Failure
CRD-733 treatment reduced or reversed several markers of heart failure and reversed pressure overload-induced cardiac hypertrophy in animal models
November 12, 2018 09:00 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, [...]
